ライブラリ登録: Guest
Critical Reviews™ in Therapeutic Drug Carrier Systems

年間 6 号発行

ISSN 印刷: 0743-4863

ISSN オンライン: 2162-660X

The Impact Factor measures the average number of citations received in a particular year by papers published in the journal during the two preceding years. 2017 Journal Citation Reports (Clarivate Analytics, 2018) IF: 2.7 To calculate the five year Impact Factor, citations are counted in 2017 to the previous five years and divided by the source items published in the previous five years. 2017 Journal Citation Reports (Clarivate Analytics, 2018) 5-Year IF: 3.6 The Immediacy Index is the average number of times an article is cited in the year it is published. The journal Immediacy Index indicates how quickly articles in a journal are cited. Immediacy Index: 0.8 The Eigenfactor score, developed by Jevin West and Carl Bergstrom at the University of Washington, is a rating of the total importance of a scientific journal. Journals are rated according to the number of incoming citations, with citations from highly ranked journals weighted to make a larger contribution to the eigenfactor than those from poorly ranked journals. Eigenfactor: 0.00023 The Journal Citation Indicator (JCI) is a single measurement of the field-normalized citation impact of journals in the Web of Science Core Collection across disciplines. The key words here are that the metric is normalized and cross-disciplinary. JCI: 0.39 SJR: 0.42 SNIP: 0.89 CiteScore™:: 5.5 H-Index: 79

Indexed in

Current Development of Oral Taxane Formulations: A Review

巻 37, 発行 3, 2020, pp. 205-227
DOI: 10.1615/CritRevTherDrugCarrierSyst.2020029699
Get accessGet access

要約

In this review, we describe the advances in oral drug delivery approaches for taxanes for successful therapeutic outcome. Taxanes (paclitaxel and docetaxel) have unwanted pharmacokinetic profiles when they are given in their current dosage forms. Taxanes have low bioavailability, are extensively metabolized by CYP3A, and have a high affinity for P-glycoprotein. Regardless of dosage schedule, the overall docetaxel or paclitaxel dose that a patient can tolerate at a given interval remains similar. Currently, there are no commercially available oral taxane nanoformulations, and there are still several challenges to overcome. Nano-based formulations may offer the best solutions to problems involving the safety and effectiveness of taxane delivery. Thus, further research is necessary before such taxane nanoformulations can be manufactured for clinical use.

参考
  1. Misra R, Acharya S, Sahoo SK. Cancer nanotechnology: Application of nanotechnology in cancer therapy. Drug Discov Today. 2010;15(19-20):842-50.

  2. Nie S, Xing Y, Kim GJ, Simons JW. Nanotechnology applications in cancer. Annu Rev Biomed Eng. 2007;9(1):257-88.

  3. Singh R, Lillard JW. Nanoparticle-based targeted drug delivery. Exp Mol Pathol. 2009;86(3):215-23. PubMed PMID: PMC3249419.

  4. Fernandes C, Soni U, Patravale V. Nano-interventions for neurodegenerative disorders. Pharmacol Res. 2010;62(2):166-78.

  5. Singh R, Lillard JW Jr. Nanoparticle-based targeted drug delivery. Exp Mol Pathol. 2009;86(3):215-23. PubMed PMID: 19186176. Pubmed Central PMCID: PMC3249419. Epub 2009/02/03.eng.

  6. Soppimath KS, Aminabhavi TM, Kulkarni AR, Rudzinski WE. Biodegradable polymeric nanoparticles as drug delivery devices. J Control Release. 2001;70(1):1-20.

  7. Bamrungsap S, Zhao Z, Chen T, Wang L, Li C, Fu T, Tan W. Nanotechnology in therapeutics: A focus on nanoparticles as a drug delivery system. Nanomedicine. 2012;7(8):1253-71. PubMed PMID: 22931450. Epub 2012/08/31.eng.

  8. Steichen SD, Caldorera-Moore M, Peppas NA. A review of current nanoparticle and targeting moieties for the delivery of cancer therapeutics. Eur J Pharm Sci. 2013;48(3):416-27. PubMed PMID: PMC3619023.

  9. Mody VV, Cox A, Shah S, Singh A, Bevins W, Parihar H. Magnetic nanoparticle drug delivery systems for targeting tumor. Appl Nanosci. 2014;4(4):385-92.

  10. De Haan P, Lerk CF. Oral controlled release dosage forms. A review. Pharm Weekbl Sci. 1984 Apr 27;6(2):57-67. PubMed PMID: 6374610. Epub 1984/04/27.eng.

  11. De Jong WH, Borm PJA. Drug delivery and nanoparticles: Applications and hazards. Int J Nanomedicine. 2008;3(2):133-49. PubMed PMID: PMC2527668.

  12. Verma G, Rajagopalan MD, Valluru R, Sridhar KA. Nanoparticles: A novel approach to target tumors. In: Grumezescu AM, editor. Nano- and microscale drug delivery systems: Design and fabrication. Amsterdam: Elsevier; 2017. p 113-29.

  13. Gupta AP, Pandotra P, Kushwaha M, Khan S, Sharma R, Gupta S. Alkaloids: A source of anticancer agents from nature. In: Atta-ur-Rahman, editor. Studies in natural products chemistry. 2015; 46:113-129.

  14. Wang HK. Plant-derived anticancer agents currently in clinical use or in clinical trials. IDrugs. 1998;1(1):92-102. PubMed PMID: 18465513. Epub 2008/05/10.eng.

  15. Zhang L, Zhang N. How nanotechnology can enhance docetaxel therapy. Int J Nanomedicine. 2013;8:2927-41. PubMed PMID: 23950643. Pubmed Central PMCID: PMC3742154. Epub 2013/08/21.eng.

  16. Tan Q, Liu X, Fu X, Li Q, Dou J, Zhai G. Current development in nanoformulations of docetaxel. Expert Opin Drug Deliv. 2012;9(8):975-90. PubMed PMID: 22703284. Epub 2012/06/19.eng.

  17. Miele E, Spinelli GP, Miele E, Tomao F, Tomao S. Albumin-bound formulation of paclitaxel (Abraxane ABI-007) in the treatment of breast cancer. Int J Nanomedicine. 2009;4:99-105. PubMed PMID: PMC2720743.

  18. Sharma M, Sharma R, Jain DK. Nanotechnology based approaches for enhancing oral bioavailability of poorly water soluble antihypertensive drugs. Scientifica. 2016;2016:8525679.

  19. Date AA, Hanes J, Ensign LM. Nanoparticles for oral delivery: Design, evaluation and state-of-the-art. J Control Release. 2016;240:504-26. PubMed PMID: PMC5064878.

  20. Feng L, Mumper RJ. A critical review of lipid-based nanoparticles for taxane delivery. Cancer Lett. 2013;334(2):157-75.

  21. Bissery MC, Nohynek G, Sanderink GJ, Lavelle F. Docetaxel (Taxotere): A review of preclinical and clinical experience. Part I: Preclinical experience. Anticancer Drugs. 1995;6(3):339-55, 363-8. PubMed PMID: 7670132. Epub 1995/06/01.eng.

  22. Feng L, Mumper RJ. A critical review of lipid-based nanoparticles for taxane delivery. Cancer Lett. 2013;334(2):157-75. PubMed PMID: PMC3485436.

  23. Yared JA, Tkaczuk KHR. Update on taxane development: New analogs and new formulations. Drug Des Devel Ther. 2012;6:371-84. PubMed PMID: PMC3523563.

  24. Rossi A, Cova D, Leo S, Repetto L. Impact of the physiological effects of aging on the pharmacokinetics and pharmacodynamics of systemic lung cancer treatment. In: Gridelli C, Audisio RA, editors. Management of lung cancer in older people. 2013:65-87.

  25. Ma P, Mumper RJ. Paclitaxel nano-delivery systems: A comprehensive review. J Nanomed Nanotechnol. 2013;4(2):1000164. PubMed PMID: PMC3806207.

  26. Kothamasu P, Kanumur H, Ravur N, Maddu C, Parasuramrajam R, Thangavel S. Nanocapsules: The weapons for novel drug delivery systems. Bioimpacts. 2012;2(2):71-81. PubMed PMID: PMC3648923.

  27. Mora-Huertas CE, Fessi H, Elaissari A. Polymer-based nanocapsules for drug delivery. Int J Pharm. 2010;385(1-2):113-42.

  28. Liu Y, Huang L, Liu F. Paclitaxel nanocrystals for overcoming multidrug resistance in cancer. Mol Pharm. 2010;7(3):863-9. PubMed PMID: 20420443.

  29. Deng J, Huang L, Liu F. Understanding the structure and stability of paclitaxel nanocrystals. Int J Pharm. 2010;390(2):242-9. PubMed PMID: 20167270.

  30. Liu F, Park JY, Zhang Y, Conwell C, Liu Y, Bathula SR, Huang L. Targeted cancer therapy with novel high drug-loading nanocrystals. J Pharm Sci. 2010:3542-51. PubMed PMID: 20564383. Epub 2010/06/22.eng.

  31. Wang Y, Chen L, Tan L, Zhao Q, Luo F, Wei Y, Qian Z. PEG-PCL based micelle hydrogels as oral docetaxel delivery systems for breast cancer therapy. Biomaterials. 2014;35(25):6972-85. PubMed PMID: 24836952. Epub 2014/05/20.eng.

  32. Patel K, Chowdhury N, Doddapaneni R, Boakye CHA, Singh M. Piperlongumine for enhancing oral bioavailability and cytotoxicity of docetaxel in triple-negative breast cancer. J Pharm SciJ. 2015;104(12):4417-26. PubMed PMID: PMC4706797.

  33. Dou J, Zhang H, Liu X, Zhang M, Zhai G. Preparation and evaluation in vitro and in vivo of docetaxel loaded mixed micelles for oral administration. Colloids Surf B Biointerfaces. 2014;114:20-7. PubMed PMID: 24157590. Epub 2013/10/26.eng.

  34. Ganta S, Devalapally H, Amiji M. Curcumin enhances oral bioavailability and antitumor therapeutic efficacy of paclitaxel upon administration in nanoemulsion formulation. J Pharm Sci. 2010;99(11):4630-41. PubMed PMID: 20845461. Epub 2010/09/17.eng.

  35. Yin Y, Cui F, Mu C, Chung SJ, Shim CK, Kim DD. Improved solubility of docetaxel using a microemulsion delivery system: Formulation optimization and evaluation. Asian J Pharm Sci. 2009; 4(6):331-9.

  36. Sandhu PS, Beg S, Mehta F, Singh B, Trivedi P. Novel dietary lipid-based self-nanoemulsifying drug delivery systems of paclitaxel with p-gp inhibitor: Implications on cytotoxicity and biopharmaceutical performance. Expert Opin Drug Deliv. 2015;12(11):1809-22. PubMed PMID: 26144859. Epub 2015/07/07.eng.

  37. Seo YG, Kim DH, Ramasamy T, Kim JH, Marasini N, Oh YK, Kim DW, Kim JK, Yong CS, Kim JO, Choi HG. Development of docetaxel-loaded solid self-nanoemulsifying drug delivery system (SNEDDS) for enhanced chemotherapeutic effect. Int J Pharm. 2013;452(1-2):412-20. PubMed PMID: 23707964. Epub 2013/05/28.eng.

  38. Cho HJ, Park JW, Yoon IS, Kim DD. Surface-modified solid lipid nanoparticles for oral delivery of docetaxel: Enhanced intestinal absorption and lymphatic uptake. Int J Nanomedicine. 2014;9:495-504. PubMed PMID: 24531717. Pubmed Central PMCID: PMC3894956. Epub 2014/02/18.eng.

  39. Baek JS, So JW, Shin SC, Cho CW. Solid lipid nanoparticles of paclitaxel strengthened by hydroxypropyl-P-cyclodextrin as an oral delivery system. Int J Mol Med. 2012;30(4):953-9. PubMed PMID: 22859311. Epub 2012/08/04.eng.

  40. Fang G, Tang B, Chao Y, Xu H, Gou J, Zhang Y, Xu H, Tang X. Cysteine-functionalized nanostructured lipid carriers for oral delivery of docetaxel: A permeability and pharmacokinetic study. Mol Pharm. 2015;12(7):2384-95. PubMed PMID: 25974386. Epub 2015/05/15.eng.

  41. Choi JS, Jo BW. Enhanced paclitaxel bioavailability after oral administration of pegylated paclitaxel prodrug for oral delivery in rats. Int J Pharm. 2004;280(1-2):221-7. PubMed PMID: 15265561. Epub 2004/07/22.eng.

  42. Attili-Qadri S, Karra N, Nemirovski A, Schwob O, Talmon Y, Nassar T, Benita S. Oral delivery system prolongs blood circulation of docetaxel nanocapsules via lymphatic absorption. Proc Natl Acad Sci U S A. 2013;110(43):17498-503. PubMed PMID: 24101508. Pubmed Central PMCID: PMC3808655. Epub 2013/10/09.eng.

  43. Dahmani FZ, Yang H, Zhou J, Yao J, Zhang T, Zhang Q. Enhanced oral bioavailability of paclitaxel in pluronic/LHR mixed polymeric micelles: preparation, in vitro and in vivo evaluation. Eur J Pharm Sci. 2012;47(1):179-89. PubMed PMID: 22683386. Epub 2012/06/12.eng.

  44. Zhang L, Shen Y, Qiu L. Loading docetaxel in P-cyclodextrin-based micelles for enhanced oral chemo-therapy through inhibition of P-glycoprotein mediated efflux transport. RSC Adv. 2017;7(42):26161-9.

  45. Pooja D, Kulhari H, Kuncha M, Rachamalla SS, Adams DJ, Bansal V, Sistla R. Improving efficacy, oral bioavailability, and delivery of paclitaxel using protein-grafted solid lipid nanoparticles. Mol Pharm. 2016;13(11):3903-12. PubMed PMID: 27696858. Epub 2016/10/05.eng.

  46. Bu X, Zhu T, Ma Y, Shen Q. Co-administration with cell penetrating peptide enhances the oral bio-availability of docetaxel-loaded nanoparticles. Drug Dev Ind Pharm. 2015;41(5):764-71. PubMed PMID: 24669977. Epub 2014/03/29.eng.

  47. Roger E, Kalscheuer S, Kirtane A, Guru BR, Grill AE, Whittum-Hudson J, Panyam J. Folic acid functionalized nanoparticles for enhanced oral drug delivery. Mol Pharm. 2012;9(7):2103-10.

  48. Li J, Huang P, Chang L, Long X, Dong A, Liu J, Chu L, Hu F, Liu J, Deng L. Tumor targeting and pH-responsive polyelectrolyte complex nanoparticles based on hyaluronic acid-paclitaxel conjugates and Chitosan for oral delivery of paclitaxel. Macromol Res. 2013;21(12):1331-7.

  49. Croy SR, Kwon GS. Polymeric micelles for drug delivery. Curr Pharm Des. 2006;12(36):4669-84. PubMed PMID: 17168771. Epub 2006/12/16.eng.

  50. Torchilin VP. Lipid-core micelles for targeted drug delivery. Curr Drug Deliv. 2005;2(4):319-27.

  51. Khan AY, Talegaonkar S, Iqbal Z, Ahmed FJ, Khar RK. Multiple emulsions: An overview. Curr Drug Deliv. 2006;3(4):429-43. PubMed PMID: 17076645. Epub 2006/11/02.eng.

  52. Talegaonkar S, Azeem A, Ahmad FJ, Khar RK, Pathan SA, Khan ZI. Microemulsions: A novel approach to enhanced drug delivery. Recent Pat Drug Deliv Formul. 2008;2(3):238-57. PubMed PMID: 19075911. Epub 2008/12/17.eng.

  53. Jaiswal M, Dudhe R, Sharma PK. Nanoemulsion: An advanced mode of drug delivery system. 3 Biotech. 2015;5(2):123-7. PubMed PMID: PMC4362737.

  54. Anton N, Vandamme TF. Nano-emulsions and micro-emulsions: Clarifications of the critical differences. Pharm Res. 2011;28(5):978-85. PubMed PMID: 21057856. Epub 2010/11/09.eng.

  55. Uner M, Yener G. Importance of solid lipid nanoparticles (SLN) in various administration routes and future perspectives. Int J Nanomedicine. 2007;2(3):289-300. PubMed PMID: PMC2676658.

  56. Mukherjee S, Ray S, Thakur RS. Solid lipid nanoparticles: A modern formulation approach in drug delivery system. Indian J Pharm Sci. 2009;71(4):349-58. PubMed PMID: PMC2865805.

  57. Liu J, Qiu Z, Wang S, Zhou L, Zhang S. A modified double-emulsion method for the preparation of daunorubicin-loaded polymeric nanoparticle with enhanced in vitro anti-tumor activity. Biomed Mater. 2010;5(6):065002. PubMed PMID: 20924138. Epub 2010/10/07.eng.

  58. Ravi Kumar MNV, Blanco-Prieto MJ, Waterhouse DN. Nanotheraputics. Cancer Letters. 2013;334(2): 155-6.

  59. Severino P, Andreani T, Macedo AS, Fangueiro JF, Santana MH, Silva AM, Souto EB. Current state-of-art and new trends on lipid nanoparticles (SLN and NLC) for oral drug delivery. J Drug Deliv. 2012;2012:750891. PubMed PMID: PMC3228282.

  60. Das S, Chaudhury A. Recent advances in lipid nanoparticle formulations with solid matrix for oral drug delivery. AAPS PharmSciTech. 2011;12(1):62-76. PubMed PMID: PMC3066374.

  61. Fang G, Tang B, Chao Y, Zhang Y, Xu H, Tang X. Improved oral bioavailability of docetaxel by nano-structured lipid carriers: In vitro characteristics, in vivo evaluation and intestinal transport studies. RSC Adv. 2015;5(117):96437-47.

  62. Peterson LW, McKenna CE. Prodrug approaches to improving the oral absorption of antiviral nucleotide analogues. Expert Opin Drug Deliv. 2009;6(4):405-20. PubMed PMID: PMC5117106.

  63. Dragojevic S, Ryu JS, Raucher D. Polymer-based prodrugs: Improving tumor targeting and the solubility of small molecule drugs in cancer therapy. Molecules. 2015;20(12):21750-69. PubMed PMID: 26690101. Epub 2015/12/23.eng.

  64. Hu L. Prodrugs: Effective solutions for solubility, permeability and targeting challenges. IDrugs. 2004;7(8):736-42. PubMed PMID: 15334306. Epub 2004/08/31.eng.

  65. Ren G, Liu D, Guo W, Wang M, Wu C, Guo M, Ai X, Wang Y, He Z. Docetaxel prodrug liposomes for tumor therapy: Characterization, in vitro and in vivo evaluation. Drug Deliv. 2016;23(4):1272-81. PubMed PMID: 26965023. Epub 2016/03/12.eng.

  66. Saraiva C, Praja C, Ferreira R, Santos T, Ferreira L, Bernardino L. Nanoparticle-mediated brain drug delivery: Overcoming blood-brain barrier to treat neurodegenerative diseases. J Control Release. 2016;235:34-47.

  67. Von Hoff DD, Mita MM, Ramanathan RK, Weiss GJ, Mita AC, LoRusso PM, Burris HA 3rd, Hart LL, Low SC, Parsons DM, Zale SE, Summa JM, Youssoufian H, Sachdev JC. Phase I study of PSMA-targeted docetaxel-containing nanoparticle BIND-014 in patients with advanced solid tumors. Clin Cancer Res. 2016;22(13):3157-63. PubMed PMID: 26847057. Epub 2016/02/06.eng.

  68. Mahmud A, Xiong X-B, Aliabadi HM, Lavasanifar A. Polymeric micelles for drug targeting. J Drug Target. 2007;15(9):553-84.

  69. Xu W, Ling P, Zhang T. Polymeric micelles, a promising drug delivery system to enhance bioavailability of poorly water-soluble drugs. J Druf Deliv. 2013;2013:340315.

  70. Bae YH, Park K. Targeted drug delivery to tumors: Myths, reality and possibility. J Control Release. 2011;153(3):198-205. PubMed PMID: PMC3272876.

  71. Danhier F, Feron O, Preat V. To exploit the tumor microenvironment: Passive and active tumor targeting of nanocarriers for anti-cancer drug delivery. J Control Release. 2010;148(2):135-46.

  72. Bi Y, Hao F, Yan G, Teng L, Lee RJ, Xie J. Actively targeted nanoparticles for drug delivery to tumor. Curr Drug Metab. 2016;17(8):763-82. PubMed PMID: 27335116. Epub 2016/06/24.eng.

  73. Bruno BJ, Miller GD, Lim CS. Basics and recent advances in peptide and protein drug delivery. Ther Deliv. 2013;4(11):1443-67. PubMed PMID: PMC3956587.

  74. Friedman AD, Claypool SE, Liu R. The smart targeting of nanoparticles. Curr Pharm Des. 2013;19(35):6315-29. PubMed PMID: PMC4016770.

  75. Zwicke GL, Mansoori GA, Jeffery CJ. Utilizing the folate receptor for active targeting of cancer nano-therapeutics. Nano Rev. 2012;3. doi: 10.3402/nano.v3i0.18496. PubMed PMID: PMC3521101.

  76. Fakhari A, Berkland C. Applications and emerging trends of hyaluronic acid in tissue engineering, as a dermal filler, and in osteoarthritis treatment. Acta Biomater. 2013;9(7):7081-92. PubMed PMID: PMC3669638.

  77. Lv Y, Xu C, Zhao X, Lin C, Yang X, Xin X, Zhang L, Qin C, Han X, Yang L, He W, Yin L. Nanoplatform assembled from a CD44-targeted prodrug and smart liposomes for dual targeting of tumor microenvironment and cancer cells. ACS Nano. 2018;12(2):1519-36.

  78. Guastalla JP 3rd, Dieras V. The taxanes: Toxicity and quality of life considerations in advanced ovarian cancer. Br J Cancer. 2003;89(Suppl 3):S16-S22. PubMed PMID: PMC2750618.

  79. Jibodh RA, Lagas JS, Nuijen B, Beijnen JH, Schellens JH. Taxanes: Old drugs, new oral formulations. Eur J Pharmacol. 2013;717(1-3):40-6. PubMed PMID: 23660368. Epub 2013/05/11.eng.

  80. Hodges LM, Markova SM, Chinn LW, Gow JM, Kroetz DL, Klein TE, Altman RB. Very important pharmacogene summary: ABCB1 (MDR1, P-glycoprotein). Pharmacogenet Genomics. 2011;21(3):152-61. PubMed PMID: PMC3098758.

  81. Tuntland T, Ethell B, Kosaka T, Blasco F, Zang RX, Jain M, Gould T, Hoffmaster K. Implementation of pharmacokinetic and pharmacodynamic strategies in early research phases of drug discovery and development at Novartis Institute of Biomedical Research. Front Pharmacol. 2014;5:174. PubMed PMID: PMC4112793.

  82. Misiukiewicz K, Gupta V, Bakst R, Posner M. Taxanes in cancer of the head and neck. Anticancer Drugs. 2014;25(5):561-70. PubMed PMID: 24534821. Epub 2014/02/19.eng.

  83. Ojima I, Zuniga ES, Berger WT, Seitz JD. Tumor-targeting drug delivery of new-generation taxoids. Future Med Chem. 2012;4(1):33-50. PubMed PMID: PMC3282303.

  84. Patel K, Doddapaneni R, Sekar V, Chowdhury N, Singh M. Combination approach of YSA peptide anchored docetaxel stealth liposomes with oral antifibrotic agent for the treatment of lung cancer. Mol Pharm. 2016;13(6):2049-58. PubMed PMID: PMC5730456.

  85. Chowdhury N, Vhora I, Patel K, Doddapaneni R, Mondal A, Singh M. Liposomes coloaded with 6-phosphofructo-2-kinase/fructose-2, 6-biphosphatase 3 (PFKFB3) shRNA plasmid and docetaxel for the treatment of non-small cell lung cancer. Pharm Res. 2017;34(11):2371-84. PubMed PMID: PMC5754003.

  86. Gu Z, Chang M, Fan Y, Shi Y, Lin G. NGR-modified pH-sensitive liposomes for controlled release and tumor target delivery of docetaxel. Colloids Surf B Biointerfaces. 2017;160:395-405. PubMed PMID: 28965079. Epub 2017/10/02.eng.

  87. Doddapaneni R, Patel K, Chowdhury N, Singh M. Noscapine chemosensitization enhances docetaxel anticancer activity and nanocarrier uptake in triple negative breast cancer. Exp Cell Res. 2016;346(1):65-73. PubMed PMID: 27177833. Pubmed Central PMCID: PMC5117688. Epub 2016/05/15.eng.

  88. Mokhtari RB, Homayouni TS, Baluch N, Morgatskaya E, Kumar S, Das B, Yeger H. Combination therapy in combating cancer. Oncotarget. 2017;8(23):38022-43. PubMed PMID: PMC5514969.

  89. Kang L, Gao Z, Huang W, Jin M, Wang Q. Nanocarrier-mediated co-delivery of chemotherapeutic drugs and gene agents for cancer treatment. Acta Pharm Sin B. 2015;5(3):169-75. PubMed PMID: PMC4629232.

  90. Gulley JL, Madan RA, Arlen PM. Enhancing efficacy of therapeutic vaccinations by combination with other modalities. Vaccine. 2007;25(Suppl 2):B89-96. PubMed PMID: PMC2062504.

  91. Werner ME, Karve S, Sukumar R, Cummings ND, Copp JA, Chen RC, Zhang T, Wang AZ. Folate-targeted nanoparticle delivery of chemo- and radiotherapeutics for the treatment of ovarian cancer peritoneal metastasis. Biomaterials. 2011;32(33):8548-54.

  92. Patel K, Doddapaneni R, Chowdhury N, Boakye CH, Behl G, Singh M. Tumor stromal disrupting agent enhances the anticancer efficacy of docetaxel loaded PEGylated liposomes in lung cancer. Nanomedicine (Lond). 2016 Jun;11(11):1377-92. PubMed PMID: 27171485. Pubmed Central PMCID: 4910941.

  93. Doddapaneni R, Patel K, Chowdhury N, Singh M. Reversal of drug-resistance by noscapine chemo sensitization in docetaxel resistant triple negative breast cancer. Sci Rep. 2017;7:15824. PubMed PMID: PMC5696458.

  94. Zhang S, Guan J, Sun M, Zhang D, Zhang H, Sun B, Guo W, Lin B, Wang Y, He Z, Luo C, Sun J. Self-delivering prodrug-nanoassemblies fabricated by disulfide bond bridged oleate prodrug of docetaxel for breast cancer therapy. Drug Deliv. 2017;24(1):1460-9. PubMed PMID: 28950729. Epub 2017/09/28.eng.

によって引用された
  1. Zhou Man, Wen Lijuan, Wang Cui, Lei Qiao, Li Yongxiu, Yi Xiaoqing, Recent Advances in Stimuli-Sensitive Amphiphilic Polymer-Paclitaxel Prodrugs, Frontiers in Bioengineering and Biotechnology, 10, 2022. Crossref

  2. Lei Lei, Wang Xiao-Jia, Tang Shou-Ching, Novel taxanes in development: Hopes or hypes?, Critical Reviews in Oncology/Hematology, 176, 2022. Crossref

  3. Zhao Shuang, Tang Yufei, Wang Ruohan, Najafi Masoud, Mechanisms of cancer cell death induction by paclitaxel: an updated review, Apoptosis, 27, 9-10, 2022. Crossref

Begell Digital Portal Begellデジタルライブラリー 電子書籍 ジャーナル 参考文献と会報 リサーチ集 価格及び購読のポリシー Begell House 連絡先 Language English 中文 Русский Português German French Spain